Table 2.

Summary of secondary efficacy endpoints (FAS).

Week 24	Adjusted mean change from baseline (SE)*		Chi-square†	LS mean difference	p-value
	Tacrolimus	Placebo
Osserman’s classification score			2.85		0.092
MG-ADL score	−3.7 (0.4)	−2.8 (0.4)		−0.9 (–2.0–0.2)	0.099
MMT score
Manual muscle test	−12.4 (1.2)	−9.3 (1.3)		−3.0 (–6.7–0.6)	0.097
Cranial nerves muscle force	−4.9 (0.5)	−3.9 (0.6)		−1.0 (–2.5–0.5)	0.201
Human body muscle force	−7.5 (0.9)	−5.4 (1.0)		−2.1 (–4.9–0.7)	0.137
GC dose change (mg/day)	−16.4 (2.5)	−15.3 (2.7)		−1.1 (–8.5–6.3)	0.767
Patients who completed the trial (%)	86.4	89.5	−	−	0.745‡

^*A generalized linear model, using the observed cases to compare the difference in the change of MG-ADL, MMT and GC dose from baseline. The response variable was the difference in indication at baseline and at the end of the trial. Baseline score was the covariate and treatment group was the fixed effect; ^† A non-parametric Mann–Whitney U test was used to compare the Osserman’s classification change from baseline between the treatment groups. ^‡ Fisher’s exact test was used to compare the number of patients who completed the trial between treatment groups.

FAS, full analysis set; GC, glucocorticoid; LS, least squares; MG-ADL, myasthenia gravis-related activities of daily living; MMT, manual muscle test; SE, standard error.